title: Subacute oral toxicity study of bisphenol F based on the draft protocol for the "Enhanced OECD Test Guideline no. 407".
abstract: Since bisphenol F (4,4'-dihydroxydiphenylmethane) has been reported to exhibit estrogen agonistic properties in the uterotrophic assay, we performed a 28-day repeated-dose toxicity study (enhanced OECD test guideline No. 407) on bisphenol F based on the OECD draft protocols to determine whether it has endocrine-mediated properties. Bisphenol F was orally administered at doses 0, 20, 100 and 500 mg/kg per day for at least 28 days, but no clear endocrine-mediated changes were detected, and it was concluded to have no endocrine-mediated effects in young adult rats. On the other hand, the main effect of bisphenol F was concluded to be liver toxicity based on clinical biochemical parameters and liver weight, but without histopathological changes. The no-observed-effect level for bisphenol F is concluded to be under 20 mg/kg per day since decreased body weight accompanied by decreased serum total cholesterol, glucose, and albumin values were observed in the female rats given 20 mg/kg per day or higher doses of bisphenol F.
authors.affiliation: Chemicals Evaluation and Research Institute, 3-822, Ishii, Hita, Oita, 877-0061, Japan. higashihara-nobuhiko@ceri.jp
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Higashihara
authors.forename: Keiji
authors.initials: K
authors.lastname: Shiraishi
authors.forename: Katusi
authors.initials: K
authors.lastname: Miyata
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Oshima
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Minobe
authors.forename: Kanji
authors.initials: K
authors.lastname: Yamasaki
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D052244:Endocrine Disruptors / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D017408:Guidelines as Topic / Q000592:standards*; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D019055:No-Observed-Adverse-Effect Level; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D011960:Receptors, Estrogen / Q000819:agonists; D012737:Sex Factors; D013974:Thyroxine / Q000097:blood; D018675:Toxicity Tests / Q000379:methods / Q000592:standards*; D014284:Triiodothyronine / Q000097:blood; D000098833:Bisphenol F Compounds
chemical_list: D001559:Benzhydryl Compounds; D001786:Blood Glucose; D002784:Cholesterol; D052244:Endocrine Disruptors; D011960:Receptors, Estrogen; D013974:Thyroxine; D014284:Triiodothyronine; C008745:4,4'-bisphenol F; D000098833:Bisphenol F Compounds